Glenmark Pharmaceuticals ,Hikma enter join hands for commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in US Medical Dialogues Bureau28 Feb 2020 2:42 PM ISTRyaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray...
Glenmark completes phase 3 study for nasal spray Ruby Khatun Khatun15 Dec 2017 10:15 AM ISTNew Delhi: Glenmark Pharmaceuticals said it has completed phase 3 study of its investigational fixed-dose combination nasal spray and plans to submit...